SCHEMBL4716836

SCHEMBL4716836

Cc1ccnc(NCCCCN)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.45
DYRK1B Q9Y463 2/20 0.44
PIM1 P11309 1/20 0.44
PIM2 Q9P1W9 1/20 0.44
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
CXCR4 P61073 1/20 0.43
DNM2 P50570 2/20 0.43
STK17A Q9UEE5 1/20 0.43
HRH4 Q9H3N8 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
AURKA O14965 1/20 0.41
JAK1 P23458 1/20 0.41
KDR P35968 1/20 0.41
SYK P43405 1/20 0.41
KCNH2 Q12809 1/20 0.41
LRRK2 Q5S007 1/20 0.41
AURKB Q96GD4 1/20 0.41
FERMT2 Q96AC1 1/20 0.40
HSP90AA1 P07900 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13034199 0.88 CXCR4 (0.54) MAPTCYP2C9CXCR4NPSR1SYK
SCHEMBL28248600 0.85 DNM2 (0.57) MAPTDNM2HRH4NPSR1
SCHEMBL13403107 0.83 HRH4 (0.56) MAPTCYP2C9DNM2HRH4NPSR1
SCHEMBL13484616 0.81 NUDT1 (0.49) MAPTCYP2C9DNM2HRH4NPSR1
SCHEMBL91452 0.79 NPSR1 (0.46) MAPTCYP2C9DNM2HRH4NPSR1
SCHEMBL13524816 0.79 EIF2AK2 (0.54) MAPTCYP2C9DNM2HRH4NPSR1
SCHEMBL12280402 0.78 DYRK1B (0.46) HRH3DYRK1BPIM1PIM2DNM2
SCHEMBL10625591 0.77 KMT2A (0.55) DNM2
SCHEMBL10225045 0.77 MAPK1 (0.59) MAPTCYP2C9NPSR1
SCHEMBL28661902 0.77 DNM2 (0.64) HRH3DYRK1BDNM2STK17AHRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216230-B1 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC (US) 2008-04-23 EP disclosed
US-6514964-B1 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors AMGEN INC. 2003-02-04 US disclosed